November 2014

Cell Based Assays 11 - 12 November 2014, London UK

Clinical failure in the pharmaceutical industry remains at a phenomenal 90%. Failed drugs are costly both financially and in terms of human suffering. As a result there is an urgent need in pharmaceutical and academic research for efficient and innovative processes enabling more relevant, predictive and functional cell-based assays in the drug discovery process.

Returning for its seventh year as the industry pioneering and leading event, SMI are proud to present the 7th annual Advances in Cell Based Assays Conference, 11th-12th November, 2014, London. This event will explore latest trends and topics impacting cell based assays, discussed in an open and dynamic environment.

Come along and be part of a major networking opportunity allowing you to benchmark against the best practice strategies employed. You will hear case studies, presentations and round table discussions on the key issues in this sector delivered by a first-class speaking faculty.

Key Topics Include:

• 3D model of human epidermal equivalent (HEE)
• Translating drug combinations from in vitro to clinic – 2D Or 3D cultures
• Phenotypic screening technology as a powerful compound profiling platform
• High Throughput image-Based cell Screening
• Cell based assays for biologics targeting GPCR
• Label Fee- the way to be? Label free technology as a way to innovate medicine

Clinical Trials in CNS 11–12 November 2014 London, United Kingdom

SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society. The economic and social costs of neurodegenerative disorders to society are huge. Many big pharmaceutical companies have moved away from CNS research.

With this comes the need for new and improved therapies for treating neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.

This conference will give delegates an opportunity to gain additional insights into the best practices in clinical trials, as well as addressing the challenges in CNS research and by looking at the latest pre-clinical and clinical studies. This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.

Cell Based Assays 11 - 12 November 2014, London UK

Clinical failure in the pharmaceutical industry remains at a phenomenal 90%. Failed drugs are costly both financially and in terms of human suffering. As a result there is an urgent need in pharmaceutical and academic research for efficient and innovative processes enabling more relevant, predictive and functional cell-based assays in the drug discovery process.

Returning for its seventh year as the industry pioneering and leading event, SMI are proud to present the 7th annual Advances in Cell Based Assays Conference, 11th-12th November, 2014, London. This event will explore latest trends and topics impacting cell based assays, discussed in an open and dynamic environment.

Come along and be part of a major networking opportunity allowing you to benchmark against the best practice strategies employed. You will hear case studies, presentations and round table discussions on the key issues in this sector delivered by a first-class speaking faculty.

Key Topics Include:

• 3D model of human epidermal equivalent (HEE)
• Translating drug combinations from in vitro to clinic – 2D Or 3D cultures
• Phenotypic screening technology as a powerful compound profiling platform
• High Throughput image-Based cell Screening
• Cell based assays for biologics targeting GPCR
• Label Fee- the way to be? Label free technology as a way to innovate medicine

Clinical Trials in CNS 11–12 November 2014 London, United Kingdom

SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society. The economic and social costs of neurodegenerative disorders to society are huge. Many big pharmaceutical companies have moved away from CNS research.

With this comes the need for new and improved therapies for treating neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.

This conference will give delegates an opportunity to gain additional insights into the best practices in clinical trials, as well as addressing the challenges in CNS research and by looking at the latest pre-clinical and clinical studies. This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.